NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer and 360 gene expression, protein immune profiling, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, nCounter Vantage 3D, miRNA expression, cancer copy number variation, and other gene expression panels. Further, the company offers nCounter-based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc., as well as the Cancer Therapy Evaluation Program of the National Cancer Institute. The company was founded in 2003 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone206-378-6266
Debt
Current Ratio3.62
Quick Ratio3.22
Price-To-Earnings
Sales & Book Value
Annual Sales$114.90 million
Price / Sales5.59
Price / Cash FlowN/A
Price / Book13.20
Profitability
Net Income$-43,560,000.00
Net Margins-58.11%
Return on Assets-50.85%
Miscellaneous
Employees467
OptionableOptionable
NanoString Technologies (NASDAQ:NSTG) Frequently Asked Questions
What is NanoString Technologies' stock symbol?
NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."
How were NanoString Technologies' earnings last quarter?
NanoString Technologies Inc (NASDAQ:NSTG) announced its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.01. The biotechnology company earned $28.62 million during the quarter, compared to analyst estimates of $25.90 million. NanoString Technologies had a negative return on equity of 206.80% and a negative net margin of 58.11%. View NanoString Technologies' Earnings History.
When is NanoString Technologies' next earnings date?
What guidance has NanoString Technologies issued on next quarter's earnings?
NanoString Technologies issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $106-107 million, compared to the consensus revenue estimate of $105.2 million.NanoString Technologies also updated its Q4 2018 guidance to EPS.
What price target have analysts set for NSTG?
4 analysts have issued 1 year price targets for NanoString Technologies' stock. Their forecasts range from $18.00 to $23.00. On average, they expect NanoString Technologies' share price to reach $19.75 in the next year. This suggests that the stock has a possible downside of 5.3%. View Analyst Price Targets for NanoString Technologies.
What is the consensus analysts' recommendation for NanoString Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.
Has NanoString Technologies been receiving favorable news coverage?
Headlines about NSTG stock have trended positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NanoString Technologies earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near term.
Who are some of NanoString Technologies' key competitors?
Some companies that are related to NanoString Technologies include China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Spark Therapeutics (ONCE), Autolus Therapeutics (AUTL), Editas Medicine (EDIT), Rubius Therapeutics (RUBY), Sangamo Therapeutics (SGMO) and Iovance Biotherapeutics (IOVA).
Who are NanoString Technologies' key executives?
NanoString Technologies' management team includes the folowing people:
- Mr. R. Bradley Gray, CEO, Pres & Director (Age 42)
- Mr. J. Chad Brown, Sr. VP of Sales & Marketing (Age 61)
- Dr. Joseph M. Beechem, Sr. VP of R&D (Age 61)
- Mr. K. Thomas Bailey, CFO & Treasurer (Age 50)
- Dr. Mary Tedd Allen, Sr. VP of Operations (Age 56)
How do I buy shares of NanoString Technologies?
Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NanoString Technologies' stock price today?
One share of NSTG stock can currently be purchased for approximately $20.85.
How big of a company is NanoString Technologies?
NanoString Technologies has a market capitalization of $667.81 million and generates $114.90 million in revenue each year. The biotechnology company earns $-43,560,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. NanoString Technologies employs 467 workers across the globe.
What is NanoString Technologies' official website?
How can I contact NanoString Technologies?
NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]
MarketBeat Community Rating for NanoString Technologies (NASDAQ NSTG)
MarketBeat's community ratings are surveys of what our community members think about NanoString Technologies and other stocks. Vote "Outperform" if you believe NSTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
